Forced Degradation Studies of Ivabradine and In Silico Toxicology Predictions for Its New Designated Impurities

被引:13
作者
Pikul, Piotr [1 ]
Jamrogiewicz, Marzena [1 ]
Nowakowska, Joanna [1 ]
Hewelt-Belka, Weronika [2 ,3 ]
Ciura, Krzesimir [1 ]
机构
[1] Med Univ Gdansk, Dept Phys Chem, Fac Pharm Subfac Lab Med, Gdansk, Poland
[2] Gdansk Univ Technol, Dept Analyt Chem, Fac Chem, Gdansk, Poland
[3] Pomeranian Sci & Technol Pk, Mass Spectrometry & Chromatog Lab, Gdynia, Poland
来源
FRONTIERS IN PHARMACOLOGY | 2016年 / 7卷
关键词
ivabradine; stress testing; stability; LC-MS/MS; in silica; ADME/Tox calculations; STABILITY; PHARMACEUTICALS; PRODUCTS; DRUGS;
D O I
10.3389/fphar.2016.00117
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
All activities should aim to eliminate genotoxic impurities and/or protect the API against degradation. There is a necessity to monitor impurities from all classification groups, hence ivabradine forced degradation studies were performed. Ivabradine was proved to be quite durable active substance, but still new and with insufficient stability data. Increased temperature, acid, base, oxidation reagents and light were found to cause its degradation. Degradation products were determined with the usage of HPLC equipped with Q-TOF-MS detector. Calculations of pharmacological and toxicological properties were performed for six identified degradation products. Target prediction algorithm was applied on the basis of Hyperpolarization-actiyated cyclic nucleotide-gated cation channels, as well as more general parameters like logP and aqueous solubility. Ames test and five cytochromes activities were calculated for toxicity assessment for selected degradation products. Pharmacological activity of photodegradation product (UV4), which is known as active metabolite, was qualified and identified. Two other degradation compounds (0x1 and N1), which were formed during degradation process, were found to be pharmacologically active.
引用
收藏
页数:12
相关论文
共 27 条
[1]   Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery [J].
Alavijeh M.S. ;
Chishty M. ;
Qaiser M.Z. ;
Palmer A.M. .
NeuroRX, 2005, 2 (4) :554-571
[2]  
[Anonymous], CPMPSWP519902 EMEA
[3]   In silico predictions of drug solubility and permeability:: Two rate-limiting barriers to oral drug absorption [J].
Bergström, CAS .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2005, 96 (03) :156-161
[4]  
Carstensen JT., 2000, Drug Stability: Principles and Practices, V3rd
[5]   The cytochrome P450 superfamily: Biochemistry, evolution and drug metabolism in humans [J].
Danielson, PB .
CURRENT DRUG METABOLISM, 2002, 3 (06) :561-597
[6]   The Role of the Funny Current in Pacemaker Activity [J].
DiFrancesco, Dario .
CIRCULATION RESEARCH, 2010, 106 (03) :434-446
[7]   The assessment of impurities for genotoxic potential and subsequent control in drug substance and drug product [J].
Dow, Linda K. ;
Hansen, Marvin M. ;
Pack, Brian W. ;
Page, Todd J. ;
Baertschi, Steven W. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 102 (05) :1404-1418
[8]   Simultaneous determination of ivabradine and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry [J].
François-Bouchard, M ;
Simonin, G ;
Bossant, MJ ;
Boursier-Neyret, C .
JOURNAL OF CHROMATOGRAPHY B, 2000, 745 (02) :261-269
[9]   SwissTargetPrediction: a web server for target prediction of bioactive small molecules [J].
Gfeller, David ;
Grosdidier, Aurelien ;
Wirth, Matthias ;
Daina, Antoine ;
Michielin, Olivier ;
Zoete, Vincent .
NUCLEIC ACIDS RESEARCH, 2014, 42 (W1) :W32-W38
[10]   The thermal and photostability of solid pharmaceuticals -: A review [J].
Glass, BD ;
Novák, C ;
Brown, ME .
JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY, 2004, 77 (03) :1013-1036